FAP and renal cell carcinoma: A final consideration is that in recent years, the role of other radiotracers (e.g., [89Zr]Girentuximab or radiolabeled FAP inhibitors) in the detection of RCC metastases has been emerging; as these tracers may have greater diagnostic accuracy than [18F]FDG-PET/CT, their role in this setting should be investigated with further studies.